CAR's made it to the pancreas
Despite intensive treatment, pancreatic adenocarcinoma still has the worst prognosis among all malignancies. Using clinically relevant models, we demonstrated the therapeutic efficacy of adoptively transferred T cells engineered with a carcinoembryonic antigen (CEA)- and ERBB2-specific chimeric anti...
Gespeichert in:
| Veröffentlicht in: | Oncoimmunology 2012-11, Vol.1 (8), p.1387-1389 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1389 |
|---|---|
| container_issue | 8 |
| container_start_page | 1387 |
| container_title | Oncoimmunology |
| container_volume | 1 |
| creator | Chmielewski, Markus Maliar, Amit Eshhar, Zelig Abken, Hinrich |
| description | Despite intensive treatment, pancreatic adenocarcinoma still has the worst prognosis among all malignancies. Using clinically relevant models, we demonstrated the therapeutic efficacy of adoptively transferred T cells engineered with a carcinoembryonic antigen (CEA)- and ERBB2-specific chimeric antigen receptor against pancreatic carcinoma. Targeting CD24, a putative cancer stem cell antigen expressed by a minority of carcinoma cells, was likewise effective. |
| doi_str_mv | 10.4161/onci.22195 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826564677</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826564677</sourcerecordid><originalsourceid>FETCH-LOGICAL-c522t-8feecd03a74def3112bece9c6d93f018728fc77e651d9ee407a15ab296bbe5653</originalsourceid><addsrcrecordid>eNqFkVFrFDEUhUNR2lL74ntl3pTC1txkksyACGVptdC6UBR8C5nkpo3MTNZk1rL_vmm3bhUE85JAvnPuyQkhr4Ge1CDhfRxtOGEMWrFD9hlINqsp-_5iewbYI4c5_6BlSSokb3fJHuOs5pKyfXI0P71-m6vBOKzCVE2xmm6xWprRJjT5FXnpTZ_x8Gk_IN_Oz77OP88uF58u5qeXMysYm2aNR7SOcqNqh54DsA4ttla6lnsKjWKNt0qhFOBaxJoqA8J0rJVdh0IKfkA-bnyXq25AZ3Gckun1MoXBpLWOJui_b8Zwq2_iL80FNAKgGLx7Mkjx5wrzpIeQLfa9GTGusoaGSSFrqVRBjzeoTTHnhH47Bqh-qFQ_VKofKy3wmz-DbdHfBRag3gBlksPchZhtwNHiM0qBLb7MFxdXV5Qpda2XzhfZh__ISogYhmE1xj7erLVJU7A9bmOJjTyMPqbB3MXUOz2ZdR-TT-XzQtb8H8-5BwAMrDU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826564677</pqid></control><display><type>article</type><title>CAR's made it to the pancreas</title><source>PubMed Central</source><creator>Chmielewski, Markus ; Maliar, Amit ; Eshhar, Zelig ; Abken, Hinrich</creator><creatorcontrib>Chmielewski, Markus ; Maliar, Amit ; Eshhar, Zelig ; Abken, Hinrich</creatorcontrib><description>Despite intensive treatment, pancreatic adenocarcinoma still has the worst prognosis among all malignancies. Using clinically relevant models, we demonstrated the therapeutic efficacy of adoptively transferred T cells engineered with a carcinoembryonic antigen (CEA)- and ERBB2-specific chimeric antigen receptor against pancreatic carcinoma. Targeting CD24, a putative cancer stem cell antigen expressed by a minority of carcinoma cells, was likewise effective.</description><identifier>ISSN: 2162-4011</identifier><identifier>ISSN: 2162-402X</identifier><identifier>EISSN: 2162-402X</identifier><identifier>DOI: 10.4161/onci.22195</identifier><identifier>PMID: 23243602</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>adoptive cell therapy ; Binding ; Biology ; Bioscience ; Calcium ; Cancer ; cancer stem cell ; Cell ; chimeric antigen receptor ; Cycle ; Landes ; Organogenesis ; pancreas adenocarcinoma ; Point of View ; Proteins ; T cell</subject><ispartof>Oncoimmunology, 2012-11, Vol.1 (8), p.1387-1389</ispartof><rights>Copyright © 2012 Landes Bioscience 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c522t-8feecd03a74def3112bece9c6d93f018728fc77e651d9ee407a15ab296bbe5653</citedby><cites>FETCH-LOGICAL-c522t-8feecd03a74def3112bece9c6d93f018728fc77e651d9ee407a15ab296bbe5653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518511/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518511/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23243602$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chmielewski, Markus</creatorcontrib><creatorcontrib>Maliar, Amit</creatorcontrib><creatorcontrib>Eshhar, Zelig</creatorcontrib><creatorcontrib>Abken, Hinrich</creatorcontrib><title>CAR's made it to the pancreas</title><title>Oncoimmunology</title><addtitle>Oncoimmunology</addtitle><description>Despite intensive treatment, pancreatic adenocarcinoma still has the worst prognosis among all malignancies. Using clinically relevant models, we demonstrated the therapeutic efficacy of adoptively transferred T cells engineered with a carcinoembryonic antigen (CEA)- and ERBB2-specific chimeric antigen receptor against pancreatic carcinoma. Targeting CD24, a putative cancer stem cell antigen expressed by a minority of carcinoma cells, was likewise effective.</description><subject>adoptive cell therapy</subject><subject>Binding</subject><subject>Biology</subject><subject>Bioscience</subject><subject>Calcium</subject><subject>Cancer</subject><subject>cancer stem cell</subject><subject>Cell</subject><subject>chimeric antigen receptor</subject><subject>Cycle</subject><subject>Landes</subject><subject>Organogenesis</subject><subject>pancreas adenocarcinoma</subject><subject>Point of View</subject><subject>Proteins</subject><subject>T cell</subject><issn>2162-4011</issn><issn>2162-402X</issn><issn>2162-402X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNqFkVFrFDEUhUNR2lL74ntl3pTC1txkksyACGVptdC6UBR8C5nkpo3MTNZk1rL_vmm3bhUE85JAvnPuyQkhr4Ge1CDhfRxtOGEMWrFD9hlINqsp-_5iewbYI4c5_6BlSSokb3fJHuOs5pKyfXI0P71-m6vBOKzCVE2xmm6xWprRJjT5FXnpTZ_x8Gk_IN_Oz77OP88uF58u5qeXMysYm2aNR7SOcqNqh54DsA4ttla6lnsKjWKNt0qhFOBaxJoqA8J0rJVdh0IKfkA-bnyXq25AZ3Gckun1MoXBpLWOJui_b8Zwq2_iL80FNAKgGLx7Mkjx5wrzpIeQLfa9GTGusoaGSSFrqVRBjzeoTTHnhH47Bqh-qFQ_VKofKy3wmz-DbdHfBRag3gBlksPchZhtwNHiM0qBLb7MFxdXV5Qpda2XzhfZh__ISogYhmE1xj7erLVJU7A9bmOJjTyMPqbB3MXUOz2ZdR-TT-XzQtb8H8-5BwAMrDU</recordid><startdate>20121101</startdate><enddate>20121101</enddate><creator>Chmielewski, Markus</creator><creator>Maliar, Amit</creator><creator>Eshhar, Zelig</creator><creator>Abken, Hinrich</creator><general>Taylor & Francis</general><general>Landes Bioscience</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20121101</creationdate><title>CAR's made it to the pancreas</title><author>Chmielewski, Markus ; Maliar, Amit ; Eshhar, Zelig ; Abken, Hinrich</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c522t-8feecd03a74def3112bece9c6d93f018728fc77e651d9ee407a15ab296bbe5653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>adoptive cell therapy</topic><topic>Binding</topic><topic>Biology</topic><topic>Bioscience</topic><topic>Calcium</topic><topic>Cancer</topic><topic>cancer stem cell</topic><topic>Cell</topic><topic>chimeric antigen receptor</topic><topic>Cycle</topic><topic>Landes</topic><topic>Organogenesis</topic><topic>pancreas adenocarcinoma</topic><topic>Point of View</topic><topic>Proteins</topic><topic>T cell</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chmielewski, Markus</creatorcontrib><creatorcontrib>Maliar, Amit</creatorcontrib><creatorcontrib>Eshhar, Zelig</creatorcontrib><creatorcontrib>Abken, Hinrich</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncoimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chmielewski, Markus</au><au>Maliar, Amit</au><au>Eshhar, Zelig</au><au>Abken, Hinrich</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CAR's made it to the pancreas</atitle><jtitle>Oncoimmunology</jtitle><addtitle>Oncoimmunology</addtitle><date>2012-11-01</date><risdate>2012</risdate><volume>1</volume><issue>8</issue><spage>1387</spage><epage>1389</epage><pages>1387-1389</pages><issn>2162-4011</issn><issn>2162-402X</issn><eissn>2162-402X</eissn><abstract>Despite intensive treatment, pancreatic adenocarcinoma still has the worst prognosis among all malignancies. Using clinically relevant models, we demonstrated the therapeutic efficacy of adoptively transferred T cells engineered with a carcinoembryonic antigen (CEA)- and ERBB2-specific chimeric antigen receptor against pancreatic carcinoma. Targeting CD24, a putative cancer stem cell antigen expressed by a minority of carcinoma cells, was likewise effective.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>23243602</pmid><doi>10.4161/onci.22195</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2162-4011 |
| ispartof | Oncoimmunology, 2012-11, Vol.1 (8), p.1387-1389 |
| issn | 2162-4011 2162-402X 2162-402X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826564677 |
| source | PubMed Central |
| subjects | adoptive cell therapy Binding Biology Bioscience Calcium Cancer cancer stem cell Cell chimeric antigen receptor Cycle Landes Organogenesis pancreas adenocarcinoma Point of View Proteins T cell |
| title | CAR's made it to the pancreas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A00%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CAR's%20made%20it%20to%20the%20pancreas&rft.jtitle=Oncoimmunology&rft.au=Chmielewski,%20Markus&rft.date=2012-11-01&rft.volume=1&rft.issue=8&rft.spage=1387&rft.epage=1389&rft.pages=1387-1389&rft.issn=2162-4011&rft.eissn=2162-402X&rft_id=info:doi/10.4161/onci.22195&rft_dat=%3Cproquest_pubme%3E1826564677%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826564677&rft_id=info:pmid/23243602&rfr_iscdi=true |